Lpath, Inc. is a biotechnology company focused on the discovery and development of lipidomic-based therapeutics, an emerging field of medical science whereby bioactive lipids are targeted to treat human diseases. The Company’s product candidate, ASONEP, is the systemic formulation of sonepcizumab, a humanized monoclonal antibody (mAb) against – more... sphingosine-1-phosphate (S1P). ASONEP has demonstrated compelling results in preclinical studies against multiple forms of cancers and against multiple sclerosis. The Company’s second product candidate is iSONEP, the ocular formulation of Sonepcizumab. iSONEP has demonstrated multiple mechanisms of action in ocular models of disease, including anti-angiogenesis, anti-inflammatory and anti-vascular permeability. The Company's third product candidate, Lpathomab, is a monoclonal antibody against lysophosphatidic acid (LPA).
(Source: 10-K) – less – More from ZoomInfo »
Lpath, Inc. Employer Reviews
